Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financi...(REN (R) GEL: Net sales of VOLTAREN G...),Health

Generic Products: For the fourth quarter of 2008, net sales from the company's generic products were $24.1 million compared with $19.2 million in the same period in 2007. For the twelve months ended December 31, 2008, net sales of the company's generic products were $92.3 million compared with $87.6 million in the same period in 2007.

R&D Update

Endo recently announced three new research collaborations to develop novel treatments for pain and discover potential cancer treatments. The first collaboration, with Harvard University, is focused on a new pain-drug delivery technique which targets pain-sensing neurons without affecting motor neurons. Under the terms of this agreement, Endo has received exclusive world-wide rights to the technology and will be responsible for development and commercialization of any drug candidates discovered under this agreement.

The second agreement, with Aurigene Discovery Technologies Limited, is a three-year collaboration to discover novel drug candidates to treat cancer. Aurigene will be responsible for all discovery and preclinical research activities, while Endo will be responsible for all clinical development and commercialization of drug candidates that advance into human testing. Endo will also provide research funding and milestone payments and receive worldwide rights to all intellectual property that results from this collaboration.

The third agreement, announced today, is with Grunenthal GMBH for the exclusive rights to develop and market the investigational drug axomadol in the United States and Canada. Axomadol is a patented new chemical entity discovered by Grunenthal and currently in Phase II development for the treatment of moderate to moderately severe chronic pain and diabetic peripheral ne
'/>"/>